New hope for bladder cancer patients: early access to TAR-200
NCT ID NCT06877676
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 20 times
Summary
This program offers early access to TAR-200, an experimental treatment, for people with high-risk non-muscle invasive bladder cancer who have run out of other options. Participants must have tried all standard treatments and cannot join a clinical trial. The goal is to provide treatment before the drug is officially approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.